Alendronate release from calcium phosphate cement for bone regeneration in osteoporotic conditions

46Citations
Citations of this article
88Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Osteoporosis represents a major health problem in terms of compromising bone strength and increasing the risk of bone fractures. It can be medically treated with bisphosphonates, which act systemically upon oral or venous administration. Further, bone regenerative treatments in osteoporotic conditions present a challenge. Here, we focused on the development of a synthetic bone substitute material with local diminishing effects on osteoporosis. Composites were created using calcium phosphate cement (CPC; 60 wt%) and polylactic-co-glycolic acid (PLGA; 40 wt%), which were loaded with alendronate (ALN). In vitro results showed that ALN-loaded CPC/PLGA composites presented clinically suitable properties, including setting times, appropriate compressive strength, and controlled release of ALN, the latter being dependent on composite degradation. Using a rat femoral condyle bone defect model in osteoporotic animals, ALN-loaded CPC/PLGA composites demonstrated stimulatory effects on bone formation both within and outside the defect region.

Cite

CITATION STYLE

APA

van Houdt, C. I. A., Gabbai-Armelin, P. R., Lopez-Perez, P. M., Ulrich, D. J. O., Jansen, J. A., Renno, A. C. M., & van den Beucken, J. J. J. P. (2018). Alendronate release from calcium phosphate cement for bone regeneration in osteoporotic conditions. Scientific Reports, 8(1). https://doi.org/10.1038/s41598-018-33692-5

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free